<DOC>
	<DOCNO>NCT01185860</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability danoprevir ( RO5190591 ) plus ritonavir compare danoprevir alone placebo plus ritonavir patient chronic hepatitis C genotype 1 receiving Pegasys ( peginterferon alfa-2a ) ribavirin . Patients cohort randomize receive either oral dos danoprevir , danoprevir plus ritonavir , placebo plus ritonavir . All patient receive Pegasys ( 180mcg sc weekly ) plus ribavirin ( 1000-1200mg/day po ) , option continue treatment completion study drug treatment . Anticipated time study treatment 12 week .</brief_summary>
	<brief_title>A Study Ritonavir-Boosted Danoprevir ( RO5190591 ) Combination With Pegasys Ribavirin Patients With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults , 1865 year age Chronic hepatitis C genotype 1 HCV treatment na√Øve , without sustain virologic response prior PEGINF/RBV treatment Body mass index ( BMI ) 18 35 kg/m2 , inclusive ; minimum weight 45 kg Liver cirrhosis Decompensated liver disease impair liver function Medical condition associate chronic liver disease chronic hepatitis C Positive hepatitis B HIV infection screen History alcohol consumption exceed 2 standard drink per day average course give week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>